SAN FRANCISCO & LEUVEN, Belgium–(BUSINESS WIRE)–Unlearn®, a pacesetter in AI options for medical trials, in the present day introduced outcomes from a collaboration with remynd, a Belgium-based biotech firm creating therapies for neurodegenerative ailments. The outcomes had been shared on the 2025 Alzheimer’s & Parkinson’s Drug Growth Summit in Boston.
The collaboration centered on remynd’s Part 2a medical trial of REM127, an investigational, first-generation small molecule remedy focusing on septins in sufferers with mild-to-moderate Alzheimer’s Illness (AD). The examine enrolled a restricted variety of contributors and measured adjustments in AD biomarkers over a brief remedy window.
Unlearn supported the examine by making use of its Alzheimer’s Illness-specific Digital Twin Generator (AD DTG)—a proprietary machine studying mannequin educated on knowledge from greater than 26,000 contributors throughout landmark AD datasets equivalent to ADNI, CPAD, NACC, and EPAD. The AD DTG makes use of every participant’s baseline knowledge to forecast their medical and biomarker trajectories below customary care, producing a “digital twin” for each particular person within the trial.
These digital twins served as individualized comparators, offering an extra layer of proof to assist interpret adjustments noticed within the handled inhabitants. This strategy is especially helpful in early-phase research the place small pattern sizes restrict the flexibility to attract conclusions utilizing conventional statistical strategies alone.
“It is a highly effective instance of how digital twins may help unlock insights from small research,” mentioned Steve Herne, CEO of Unlearn. “Our collaboration with remynd helped strengthen the proof behind REM127 and demonstrated the worth of utilizing AI to assist smarter, quicker medical analysis.”
“The collaboration with Unlearn and the ensuing knowledge additional will increase our confidence in our pioneering strategy in direction of reaching symptomatic reduction and illness modification in Alzheimer’s. This can assist our efforts to advance an optimized second-generation remedy,” mentioned Gerard Griffioen, Ph.D., CSO of remynd. “Digital twins provide a brand new lens for deciphering biomarker tendencies over time—particularly in early-stage trials the place each knowledge level issues.”
For extra info, go to www.unlearn.ai or comply with us on LinkedIn and X/Twitter.
